Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

and ribavirin
  • 24 weeks of total treatment, with R7128 1000mg bid in combination with pegylated interferon and ribavirin for 8 weeks, followed by a further 16 weeks of pegylated interferon and ribavirin
  • 48 weeks of total treatment, with R7128 1000mg bid in combination with pegylated interferon and ribavirin for 12 weeks, followed by a further 36 weeks of pegylated interferon and ribavirin.
  • A control arm with pegylated interferon and ribavirin for 48 weeks.
  • Patients in the 24 week arms will discontinue treatment at week 24 if they achieved a rapid virological response (RVR), defined as undetectable level of HCV RNA at week 4 ("RVR-guided"). Patients that do not achieve an RVR will continue on the standard of care until week 48.

    According to the current study design, patients will be enrolled as two cohorts, with randomization of the second larger cohort being initiated based on 12 week safety data of the first cohort.

    During 2009, we expect to provide updates on the progress of the trial.

    About R7128

    R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. R7128 has shown in vitro activity against all of the most common HCV genotypes (1, 2, 3 and 4).

    In a 4-week Phase 1 combination study that was conducted in 81 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated significant short-term antiviral activity with safety and tolerability comparable to placebo with SOC. Results from the 500mg, 1500mg and 1000mg dose cohorts (cohorts 1, 2 and 3) in 81 treatment-naive patients infected with HCV genotype 1 ind
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Pharmasset to Present at Two Upcoming Investor Conferences
    2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
    3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
    4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
    5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
    6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
    7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
    8. Pharmasset Joins Russell 3000 Index
    9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
    10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
    11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
    (Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
    (Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
    (Date:8/26/2015)... Bruno, CA. (PRWEB) , ... August 26, 2015 , ... ... major conferences to develop new business relationships with local sponsors in southern California. The ... to facilitate their drug development processes and regulatory pathways., , ...
    Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
    ... CLARA, Calif., Sept. 8 Cell Biosciences, Inc. and Alpha ... have entered into a definitive agreement providing for the acquisition ... or approximately $17.9 million in cash. This acquisition would significantly ... infrastructure and a broad protein analysis product portfolio. , ...
    ... NEW YORK, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... Company" or "AOBO"), a pharmaceutical,company dedicated to improving health ... of prescription and over the counter ("OTC"),products, today announced ... -- Morgan Stanley Healthcare Corporate Day, to ...
    ... Sept. 8, Palatin Technologies, Inc. (NYSE Amex: PTN ... ended June 30, 2009. For the year ended June 30, ... year ended June 30, 2008. Palatin,s net loss for the ... basic and diluted share, compared to a net loss of $14.4 ...
    Cached Biology Technology:Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5American Oriental Bioengineering Announces September Investor Conferences Participation 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 7
    (Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
    (Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
    (Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
    Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
    ... lower blood pressure (BP), and the diets can also be ... body weight, physical activity and alcohol intake play a role ... shown to be effective for preventing and managing hypertension. ... from 1900 to 2013 in which participants ate a vegetarian ...
    ... capture on video. Now researchers at Princeton University have achieved ... to break into and infect a cell. The technique they ... drugs via nanoparticles which are about the same size ... infection from occurring. The video reveals a virus-like particle ...
    ... or a busy airport where cold viruses and other germs ... as bees and butterflies can pick up fungal, bacterial or ... or as debilitating as influenza. But "almost nothing ... flowers," postdoctoral researcher Scott McArt and Professor Lynn Adler at ...
    Cached Biology News:Now in 3-D: Video of virus-sized particle trying to enter cell 2Now in 3-D: Video of virus-sized particle trying to enter cell 3As hubs for bees and pollinators, flowers may be crucial in disease transmission 2
    Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
    ... (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a chromogenic ... recombinant plasmids. In the ... IPTG, lac + ... whereas recombinant colonies appear ...
    ... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
    ... SuperScript™ III RNase H- ... an improved version of ... RT. Like SuperScript™ II ... DNA strand from single-stranded ...
    Biology Products: